(Q37397022)

20 August 2017

Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. (English)

1 reference

20 August 2017

0 references

Adrian M. Di Bisceglie

8

object named as

Adrian M Di Bisceglie

1 reference

20 August 2017

Chihiro Morishima

1

1 reference

20 August 2017

Mitchell L Shiffman

2

1 reference

20 August 2017

Jules L Dienstag

3

1 reference

20 August 2017

Karen L Lindsay

4

1 reference

20 August 2017

Gyongyi Szabo

5

1 reference

20 August 2017

Gregory T Everson

6

1 reference

20 August 2017

Anna S Lok

7

1 reference

20 August 2017

Marc G Ghany

9

1 reference

20 August 2017

Deepa Naishadham

10

1 reference

20 August 2017

Timothy R Morgan

11

1 reference

20 August 2017

Elizabeth C Wright

12

1 reference

20 August 2017

HALT-C Trial Group

13

1 reference

20 August 2017

language of work or name

English

0 references

publication date

12 June 2012

1 reference

The American Journal of Gastroenterology

20 August 2017

1 reference

20 August 2017

107

1 reference

20 August 2017

9

1 reference

20 August 2017

1388-1398

1 reference

https://scigraph.springernature.com/pub.10.1038/ajg.2012.137

20 August 2017

0 references

cites work

Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Peginterferon and ribavirin for chronic hepatitis C.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Type I interferons (alpha/beta) in immunity and autoimmunity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Strengths and limitations of commercial tests for hepatitis C virus RNA quantification

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Assessment of liver cirrhosis severity in 1015 patients of the Euricterus database with Campbell-Child, Pugh-Child and with ascites and ascites-nutritional state (ANS) related classifications. Euricterus Project Management Group.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Histological grading and staging of chronic hepatitis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Progression of fibrosis in chronic hepatitis C.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865099

Natural history of hepatitis C

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22688849

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22688849

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22688849

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/AJG.2012.137

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference

20 August 2017

1 reference